- Home
- LXEH vs CGTX Comparison
LXEH vs CGTX Comparison
Compare LXEH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- CGTX
- Stock Information
- Founded
- LXEH 2001
- CGTX 2007
- Country
- LXEH China
- CGTX United States
- Employees
- LXEH N/A
- CGTX N/A
- Industry
- LXEH Other Consumer Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- CGTX Health Care
- Exchange
- LXEH Nasdaq
- CGTX Nasdaq
- Market Cap
- LXEH 25.1M
- CGTX 23.1M
- IPO Year
- LXEH 2020
- CGTX 2021
- Fundamental
- Price
- LXEH $2.23
- CGTX $0.33
- Analyst Decision
- LXEH
- CGTX Strong Buy
- Analyst Count
- LXEH 0
- CGTX 5
- Target Price
- LXEH N/A
- CGTX $6.13
- AVG Volume (30 Days)
- LXEH 259.9K
- CGTX 942.4K
- Earning Date
- LXEH 05-20-2025
- CGTX 05-07-2025
- Dividend Yield
- LXEH N/A
- CGTX N/A
- EPS Growth
- LXEH N/A
- CGTX N/A
- EPS
- LXEH N/A
- CGTX N/A
- Revenue
- LXEH $4,493,795.00
- CGTX N/A
- Revenue This Year
- LXEH N/A
- CGTX N/A
- Revenue Next Year
- LXEH N/A
- CGTX N/A
- P/E Ratio
- LXEH N/A
- CGTX N/A
- Revenue Growth
- LXEH N/A
- CGTX N/A
- 52 Week Low
- LXEH $1.53
- CGTX $0.31
- 52 Week High
- LXEH $50.08
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- LXEH 33.81
- CGTX 39.84
- Support Level
- LXEH $1.96
- CGTX $0.30
- Resistance Level
- LXEH $3.30
- CGTX $0.34
- Average True Range (ATR)
- LXEH 0.48
- CGTX 0.03
- MACD
- LXEH 0.20
- CGTX -0.01
- Stochastic Oscillator
- LXEH 16.28
- CGTX 28.31
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.